首页 | 本学科首页   官方微博 | 高级检索  
     


Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer
Authors:Guru Sonpavde MD  Neeraj Agarwal MD  Gregory Russell Pond PhD  Rebecca J. Nagy MSc  Roberto H. Nussenzveig PhD  Andrew W. Hahn MD  Oliver Sartor MD  Theodore Stewart Gourdin MD  Lakshminarayanan Nandagopal MD  Elisa M. Ledet PhD  Gurudatta Naik MPH  Andrew J. Armstrong MD  MSc  Jue Wang MD  Mehmet Asim Bilen MD  Shilpa Gupta MD  Petros Grivas MD  PhD  Sumanta K. Pal MD  Richard B. Lanman MD  AmirAli Talasaz PhD  Michael B. Lilly MD
Affiliation:1. Dana-Farber Cancer Institute, Boston, Massachusetts;2. Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah;3. Ontario Clinical Oncology Group, Hamilton, Ontario, Canada;4. Guardant Health Inc, Redwood City, California;5. Tulane University, New Orleans, Louisiana;6. Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina;7. University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama;8. Duke Cancer Center, Durham, North Carolina;9. University of Arizona Cancer Center at Dignity Health St. Joseph’s Hospital and Medical Center, Phoenix, Arizona;10. Winship Cancer Institute, Emory University, Atlanta, Georgia;11. University of Minnesota, Minneapolis, Minnesota;12. University of Washington, Seattle, Washington;13. City of Hope Comprehensive Cancer Center, Duarte, California
Abstract:
Keywords:castration resistant  circulating tumor DNA (ctDNA)  failure-free survival  genomic profiling  metastatic  prostate cancer  survival
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号